BioCentury | Jan 14, 2021
Finance

With €127M series B, cancer vaccine developer IO Biotech raises second-largest European venture round in the past year

...Existing investors Novo Seeds, Lundbeckfonden Emerge and Sunstone Life Science Ventures also participated.Priyanka Belawat of HBM Partners...
BioCentury | Dec 16, 2020
Emerging Company Profile

With crossover funding already in place, Stagliano’s Neuron23 exits stealth with programs in neurology, systemic immune disease

...B round included Cowen Healthcare Investments, Acorn Bioventures, HBM Partners...
...Redmile Group, Cowen Healthcare Investments, Acorn Bioventures, HBM Partners...
BioCentury | Apr 1, 2020
Finance

Reversing course on IPO plans, iTeos draws $125M in private round with crossovers

...new investors Janus Henderson, RTW Investments and Invus. Also participating were existing investors MPM Capital, HBM Partners...
BioCentury | Jun 29, 2019
Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

...is in Phase III testing; data are expected next year. ClearBridge Investments’ Marshall Gordon and HBM Partners'...
BioCentury | Jun 29, 2019
Finance

Specialists and strong fundamentals must carry the sector in 3Q19

...we have a bit more cash on hand than we would under more normal circumstances,” HBM Partners’...
...a few blowups,” she said. “That’s keeping people away. I think people are losing confidence.” HBM Partners’...
BioCentury | May 24, 2019
Finance

How Europe’s hotspots of innovation could fuel its rise as a global player in new modalities

...LSE:IPO), AbbVie Ventures Products targeting DNA damage repair Cancer iTeos Therapeutics S.A. $75.0 Series B HBM Partners...
BioCentury | Apr 18, 2019
Financial News

Hookipa raises $84M in IPO

...held just over 5% of the biotech's shares. Boehringer Ingelheim Venture Fund, Takeda Ventures and HBM Partners...
BioCentury | Mar 25, 2019
Financial News

Biogen announces $5B stock buyback on heels of Alzheimer’s hit

...neurology business by purchasing companies like Sarepta Therapeutics Inc. (NASDAQ:SRPT) and Voyager Therapeutics Inc. (NASDAQ:VYGR). HBM Partners'...
BioCentury | Mar 22, 2019
Financial News

Hookipa proposes IPO as its cancer vaccines head towards the clinic

...12.5%, respectively. Also holding stakes greater than 5% are Boehringer Ingelheim Venture Fund, Takeda Ventures, HBM Partners...
BioCentury | Oct 6, 2018
Finance

Seeking validation

...into Vertex’s current share price. Ailsa Craig of International Biotechnology Trust and Ivo Staijen of HBM Partners...
Items per page:
1 - 10 of 99
BioCentury | Jan 14, 2021
Finance

With €127M series B, cancer vaccine developer IO Biotech raises second-largest European venture round in the past year

...Existing investors Novo Seeds, Lundbeckfonden Emerge and Sunstone Life Science Ventures also participated.Priyanka Belawat of HBM Partners...
BioCentury | Dec 16, 2020
Emerging Company Profile

With crossover funding already in place, Stagliano’s Neuron23 exits stealth with programs in neurology, systemic immune disease

...B round included Cowen Healthcare Investments, Acorn Bioventures, HBM Partners...
...Redmile Group, Cowen Healthcare Investments, Acorn Bioventures, HBM Partners...
BioCentury | Apr 1, 2020
Finance

Reversing course on IPO plans, iTeos draws $125M in private round with crossovers

...new investors Janus Henderson, RTW Investments and Invus. Also participating were existing investors MPM Capital, HBM Partners...
BioCentury | Jun 29, 2019
Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

...is in Phase III testing; data are expected next year. ClearBridge Investments’ Marshall Gordon and HBM Partners'...
BioCentury | Jun 29, 2019
Finance

Specialists and strong fundamentals must carry the sector in 3Q19

...we have a bit more cash on hand than we would under more normal circumstances,” HBM Partners’...
...a few blowups,” she said. “That’s keeping people away. I think people are losing confidence.” HBM Partners’...
BioCentury | May 24, 2019
Finance

How Europe’s hotspots of innovation could fuel its rise as a global player in new modalities

...LSE:IPO), AbbVie Ventures Products targeting DNA damage repair Cancer iTeos Therapeutics S.A. $75.0 Series B HBM Partners...
BioCentury | Apr 18, 2019
Financial News

Hookipa raises $84M in IPO

...held just over 5% of the biotech's shares. Boehringer Ingelheim Venture Fund, Takeda Ventures and HBM Partners...
BioCentury | Mar 25, 2019
Financial News

Biogen announces $5B stock buyback on heels of Alzheimer’s hit

...neurology business by purchasing companies like Sarepta Therapeutics Inc. (NASDAQ:SRPT) and Voyager Therapeutics Inc. (NASDAQ:VYGR). HBM Partners'...
BioCentury | Mar 22, 2019
Financial News

Hookipa proposes IPO as its cancer vaccines head towards the clinic

...12.5%, respectively. Also holding stakes greater than 5% are Boehringer Ingelheim Venture Fund, Takeda Ventures, HBM Partners...
BioCentury | Oct 6, 2018
Finance

Seeking validation

...into Vertex’s current share price. Ailsa Craig of International Biotechnology Trust and Ivo Staijen of HBM Partners...
Items per page:
1 - 10 of 99